Free Trial

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos logo
$157.97 -2.61 (-1.63%)
Closing price 02/20/2025 03:59 PM Eastern
Extended Trading
$137.00 -20.97 (-13.27%)
As of 07:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
0
Buy
12

Based on 13 Wall Street analysts who have issued ratings for Glaukos in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 11 have given a buy rating, and 1 has given a strong buy rating for GKOS.

Consensus Price Target

$159.42
0.92% Upside
According to the 13 analysts' twelve-month price targets for Glaukos, the average price target is $159.42. The highest price target for GKOS is $200.00, while the lowest price target for GKOS is $120.00. The average price target represents a forecasted upside of 0.92% from the current price of $157.97.
Get the Latest News and Ratings for GKOS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Glaukos and its competitors.

Sign Up

GKOS Analyst Ratings Over Time

TypeCurrent Forecast
2/22/24 to 2/21/25
1 Month Ago
1/23/24 to 1/22/25
3 Months Ago
11/24/23 to 11/23/24
1 Year Ago
2/22/23 to 2/22/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$159.42$147.75$134.55$91.80
Forecasted Upside0.92% Upside-7.80% Downside-6.57% Downside0.40% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

GKOS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GKOS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Glaukos Stock vs. The Competition

TypeGlaukosMedical CompaniesS&P 500
Consensus Rating Score
2.92
2.82
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside0.92% Upside29,063.69% Upside12.82% Upside
News Sentiment Rating
Positive News

See Recent GKOS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/19/2025Mizuho
2 of 5 stars
Anthony Petrone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$140.00 ➝ $200.00+30.72%
1/27/2025Piper Sandler
2 of 5 stars
Matt O'Brien
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$140.00 ➝ $180.00+12.15%
12/31/2024Stifel Nicolaus
4 of 5 stars
 Boost TargetBuy ➝ Buy$153.00 ➝ $175.00+17.05%
12/18/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Newitter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$152.00 ➝ $185.00+26.89%
12/11/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$145.00 ➝ $153.00+6.02%
12/11/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$132.00 ➝ $162.00+18.82%
12/6/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Antalffy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$182.00+34.12%
12/2/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Carrico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
12/2/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeEqual Weight ➝ Underweight$120.00-16.46%
11/26/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$140.00 ➝ $149.00+6.19%
11/5/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$130.00 ➝ $145.00+11.97%
8/1/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$131.00 ➝ $137.00+16.91%
5/6/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$84.00 ➝ $125.00+17.36%
5/4/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
2/22/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kaczor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:13 AM ET.


GKOS Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Glaukos is $159.42, with a high forecast of $200.00 and a low forecast of $120.00.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There is currently 1 sell rating, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GKOS shares.

According to analysts, Glaukos's stock has a predicted upside of 0.92% based on their 12-month stock forecasts.

Over the previous 90 days, Glaukos's stock had 3 upgrades and 1 downgrade by analysts.

Glaukos has been rated by research analysts at BTIG Research, Citigroup, Mizuho, Morgan Stanley, Piper Sandler, Stephens, Stifel Nicolaus, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like Glaukos more than other "medical" companies. The consensus rating score for Glaukos is 2.92 while the average consensus rating score for "medical" companies is 2.82. Learn more on how GKOS compares to other companies.


This page (NYSE:GKOS) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners